Regeneron Pharmaceuticals (REGN) Shareholder Investigation:
The investigation focuses on whether Regeneron's directors breached their oversight duties by disregarding senior management's alleged violation of Medicare's anti-kickback laws.
Regeneron's Eylea drug treats macular degeneration, the leading cause of blindness in seniors. The pricey drug, which costs over $10,000 per year, has become Regeneron's flagship product. The federal government is among Eylea's greatest sources of revenue through Medicare.
"We're focused on whether Regeneron's Board failed to monitor senior management, and if Regeneron has suffered resulting damages," said Reed Kathrein, the Hagens Berman partner leading the investigation.
If you purchased shares of Regeneron and suffered losses, click here to discuss your legal rights with Hagens Berman.
Contact:
Reed Kathrein, 844-916-0895
SOURCE Hagens Berman Sobol Shapiro LLP
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
